AR044782A1 - Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina - Google Patents

Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina

Info

Publication number
AR044782A1
AR044782A1 ARP040102087A ARP040102087A AR044782A1 AR 044782 A1 AR044782 A1 AR 044782A1 AR P040102087 A ARP040102087 A AR P040102087A AR P040102087 A ARP040102087 A AR P040102087A AR 044782 A1 AR044782 A1 AR 044782A1
Authority
AR
Argentina
Prior art keywords
formula
antagonists
useful
receptors
hyponatremia
Prior art date
Application number
ARP040102087A
Other languages
English (en)
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of AR044782A1 publication Critical patent/AR044782A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a benzazepinas sustituidas no péptidas de la fórmula (1), las cuales son útiles como antagonistas de los receptores de vasopresina para tratar afecciones asociadas con la actividad de los receptores de vasopresina tal como aquellas que involucran la resistencia vascular incrementada y la insuficiencia cardíaca, incluyendo la disfunción cardíaca congestiva, hiponatremia e hipertensión, entre otras descritas. Las composiciones farmacéuticas que comprenden un compuesto de fórmula (1) y los métodos para tratar afecciones tales como hipertensión, disfunción cardíaca congestiva, insuficiencia cardíaca, vasospasmo coronario, isquemia cardíaca, cirrosis hepática, hiponatremia, vasospasmo renal, insuficiencia renal, nefropatía diabética, edema cerebral, isquemia cerebral, accidente cerebrovascular, trombosis o retención de líquidos son también contemplados. Reivindicación 1: Un compuesto de fórmula (1), donde: uno de R1 y R2 es H y el otro es H, NR5R6, alcoxi C1-6, hidroxi, o halo; donde cada uno de R5 y R6 es independientemente H o alquilo C1-3; R3 es cloro; R45 es cloro, flúor, metoxi o metilo; o un éster C1-6, amida C1-6 o di(alquil C1-6)amida farmacéuticamente aceptable o su sal.
ARP040102087A 2003-06-17 2004-06-16 Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina AR044782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
AR044782A1 true AR044782A1 (es) 2005-10-05

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102087A AR044782A1 (es) 2003-06-17 2004-06-16 Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina

Country Status (30)

Country Link
US (2) US20040266752A1 (es)
EP (1) EP1633719B1 (es)
JP (1) JP5252614B2 (es)
KR (1) KR101086246B1 (es)
CN (1) CN100467454C (es)
AR (1) AR044782A1 (es)
AT (1) ATE444953T1 (es)
AU (1) AU2004281257C1 (es)
BR (1) BRPI0411598A (es)
CA (1) CA2529649C (es)
CL (1) CL2004001507A1 (es)
CR (1) CR8168A (es)
CY (1) CY1109585T1 (es)
DE (1) DE602004023501D1 (es)
DK (1) DK1633719T3 (es)
EA (1) EA011089B1 (es)
ES (1) ES2332724T3 (es)
HR (2) HRP20051006A2 (es)
IL (1) IL172630A (es)
ME (1) ME00320B (es)
NO (1) NO20060247L (es)
NZ (1) NZ544180A (es)
PL (1) PL1633719T3 (es)
PT (1) PT1633719E (es)
RS (1) RS20050930A (es)
SI (1) SI1633719T1 (es)
TW (1) TWI354555B (es)
UA (1) UA82236C2 (es)
WO (1) WO2005037795A2 (es)
ZA (1) ZA200600430B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529513A1 (en) * 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
WO2008036755A1 (en) * 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
EP2076517A1 (en) 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
JP5968466B2 (ja) 2012-12-26 2016-08-10 株式会社三和化学研究所 新規ベンゾアゼピン誘導体及びその医薬用途
KR102954172B1 (ko) 2021-03-05 2026-04-17 상하이 제유 파마슈티칼 컴퍼니 리미티드 신규 벤자제핀 융합 고리 유도체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH08502474A (ja) * 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ES2250432T3 (es) * 2000-07-05 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. Espirobenzoazepinas no peptidicas sustituidas, antagonistas de la vasopresina.
CA2529513A1 (en) * 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives

Also Published As

Publication number Publication date
CY1109585T1 (el) 2014-08-13
NZ544180A (en) 2009-01-31
US20070179128A1 (en) 2007-08-02
PL1633719T3 (pl) 2010-03-31
CN1835925A (zh) 2006-09-20
JP2007521272A (ja) 2007-08-02
TW200515911A (en) 2005-05-16
DE602004023501D1 (de) 2009-11-19
ME00320B (me) 2011-05-10
ZA200600430B (en) 2009-08-26
US20040266752A1 (en) 2004-12-30
ES2332724T3 (es) 2010-02-11
CA2529649A1 (en) 2005-04-28
HRP20051006A2 (en) 2006-05-31
NO20060247L (no) 2006-03-13
EP1633719B1 (en) 2009-10-07
UA82236C2 (en) 2008-03-25
AU2004281257B2 (en) 2010-02-04
WO2005037795A2 (en) 2005-04-28
EA011089B1 (ru) 2008-12-30
KR20060023157A (ko) 2006-03-13
PT1633719E (pt) 2009-11-11
WO2005037795A3 (en) 2005-07-28
IL172630A (en) 2011-10-31
AU2004281257C1 (en) 2010-07-01
AU2004281257A1 (en) 2005-04-28
JP5252614B2 (ja) 2013-07-31
TWI354555B (en) 2011-12-21
IL172630A0 (en) 2006-04-10
HRP20090606T1 (hr) 2010-01-31
CR8168A (es) 2008-09-10
RS20050930A (sr) 2008-04-04
CN100467454C (zh) 2009-03-11
SI1633719T1 (sl) 2010-01-29
KR101086246B1 (ko) 2011-11-23
MEP49108A (en) 2011-02-10
ATE444953T1 (de) 2009-10-15
BRPI0411598A (pt) 2006-08-29
EA200501831A1 (ru) 2006-06-30
US7687494B2 (en) 2010-03-30
EP1633719A2 (en) 2006-03-15
CL2004001507A1 (es) 2005-05-27
CA2529649C (en) 2012-01-31
DK1633719T3 (da) 2010-01-04

Similar Documents

Publication Publication Date Title
PE20221336A1 (es) Compuestos triciclicos sustituidos
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
AR080927A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas del receptor de v1a y un proceso para su obtencion
PL2078022T3 (pl) Spirobenzoazepiny stosowane jako antagoniści wazopresyny
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
PE20070370A1 (es) Compuestos derivados de carboxamidas como agentes fungicidas
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR074409A1 (es) Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias.
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
PE20090282A1 (es) Azetidinas como agentes antagonistas de ep2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal